Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibuprofen and phenylephrine tablets for common cold (China, Phase III)
CTR20240464Phase 3Completed
- Sponsor
- Kangzhi Pharmaceutical
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nasopharyngitis comparing Ibuprofen and phenylephrine tablets with Placebo (2 arms). Primary endpoint: Time to common cold cure. Started Feb 2024; status: completed.
02
Drugs
ibuprofen + phenylephrine hydrochloride
03
Conditions
nasopharyngitis
Beyond the preview
Go deeper on CTR20240464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240464.